Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;93(1):120-121.
doi: 10.1002/jmv.26209. Epub 2020 Jun 29.

Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm

Ioannis Andrianopoulos  1 , Athanasios Papathanasiou  1 , Georgios Papathanakos  1 , Aristeidis Chaidos  2 , Vasilios Koulouras  1
Affiliations
Comment

Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm

Ioannis Andrianopoulos et al. J Med Virol. 2021 Jan.
No abstract available

PubMed Disclaimer

Comment in

  • COVID-19: What type of cytokine storm are we dealing with?
    Monneret G, Benlyamani I, Gossez M, Bermejo-Martin JF, Martín-Fernandez M, Sesques P, Wallet F, Venet F. Monneret G, et al. J Med Virol. 2021 Jan;93(1):197-198. doi: 10.1002/jmv.26317. Epub 2020 Jul 27. J Med Virol. 2021. PMID: 32681651 Free PMC article. No abstract available.

Comment on

References

    1. Borku Uysal B, Ikitimur H, Yavuzer S, et al. ''Tociluzumab challenge: a series of cytokine storm therapy experience in hospitalized COVID‐19 pneumonia patients''. J Med Virol. 2020. 10.1002/jmv.26111 - DOI - PMC - PubMed
    1. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID‐19 related pneumonia. Eur J Intern Med. 2020;76:31‐35. 10.1016/j.ejim.2020.05.009 - DOI - PMC - PubMed
    1. Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID‐19 patients. Med Mal Infect. 2020. 10.1016/j.medmal.2020.05.001 - DOI - PMC - PubMed
    1. Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID‐19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19:102568. 10.1016/j.autrev.2020.102568 - DOI - PMC - PubMed
    1. Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single‐arm multicentre study on off‐label use of tocilizumab in patients with severe COVID‐19. Clin Exp Rheumatol. 2020;38(3):529‐532. - PubMed

Substances